JP2024547035A - 耳感染症を治療するための医薬組成物 - Google Patents

耳感染症を治療するための医薬組成物 Download PDF

Info

Publication number
JP2024547035A
JP2024547035A JP2024536463A JP2024536463A JP2024547035A JP 2024547035 A JP2024547035 A JP 2024547035A JP 2024536463 A JP2024536463 A JP 2024536463A JP 2024536463 A JP2024536463 A JP 2024536463A JP 2024547035 A JP2024547035 A JP 2024547035A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
gentamicin
pharma
mometasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024547035A5 (cg-RX-API-DMAC7.html
Inventor
マーティン,シャロン・クルーズ
ウェインガーテン,アラン
フリーハーフ,キース
ティリー,ジュリアン
Original Assignee
インターベット インターナショナル ベー. フェー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー. フェー. filed Critical インターベット インターナショナル ベー. フェー.
Publication of JP2024547035A publication Critical patent/JP2024547035A/ja
Publication of JP2024547035A5 publication Critical patent/JP2024547035A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024536463A 2021-12-20 2022-12-19 耳感染症を治療するための医薬組成物 Pending JP2024547035A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291673P 2021-12-20 2021-12-20
US63/291,673 2021-12-20
PCT/EP2022/086649 WO2023117900A1 (en) 2021-12-20 2022-12-19 A pharmaceutical composition for the treatment of otic infections

Publications (2)

Publication Number Publication Date
JP2024547035A true JP2024547035A (ja) 2024-12-26
JP2024547035A5 JP2024547035A5 (cg-RX-API-DMAC7.html) 2025-12-25

Family

ID=84942883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536463A Pending JP2024547035A (ja) 2021-12-20 2022-12-19 耳感染症を治療するための医薬組成物

Country Status (9)

Country Link
US (1) US20250049827A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452269B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547035A (cg-RX-API-DMAC7.html)
CN (1) CN118434420A (cg-RX-API-DMAC7.html)
AU (1) AU2022421489A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239989A1 (cg-RX-API-DMAC7.html)
ES (1) ES3050117T3 (cg-RX-API-DMAC7.html)
MX (1) MX2024007632A (cg-RX-API-DMAC7.html)
WO (1) WO2023117900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576589C (en) 2004-08-13 2013-11-12 Schering-Plough Ltd. Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"New Canine Ear Treatment Combines Three Powerful Agents In Once-a-day Therapy", VETCLICK/ NEWS, JPN6026016103, 2010, ISSN: 0005850019 *
"P-17 In vitro activity of posaconazole and other antifungals against Malasseziapachydermatis isolate", VETERINARY DERMATOLOGY, vol. 15, JPN6026016104, 2004, pages 46, ISSN: 0005850020 *
ANIMAL MEDICAL HOSPITAL & URGENT CARE, THE TRUTH ABOUT VETERINARY DRUG EXPIRATION DATES, JPN6026016105, 2018, ISSN: 0005850021 *
FREEDOM OF INFORMATION SUMMARY NADA 141-177 MOMETAMAX OTIC SUSPENSION FOR DOGS, JPN6026016102, 2003, ISSN: 0005850018 *

Also Published As

Publication number Publication date
EP4452269B1 (en) 2025-09-03
EP4452269A1 (en) 2024-10-30
AU2022421489A1 (en) 2024-06-06
CA3239989A1 (en) 2023-06-29
WO2023117900A1 (en) 2023-06-29
CN118434420A (zh) 2024-08-02
MX2024007632A (es) 2024-07-09
US20250049827A1 (en) 2025-02-13
ES3050117T3 (en) 2025-12-19

Similar Documents

Publication Publication Date Title
CA2862406C (en) Otic formulations, methods and devices
TWI362261B (en) Pharmaceutical composition for treatment of an infection in animals
US12478629B2 (en) Use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals
EP4452269B1 (en) A pharmaceutical composition for the treatment of otic infections
WO2010106465A1 (en) A dermaceutical cream made using sodium fusidate, clotrimazole and fluticasone propionate
AU2026201359A1 (en) Otic formulations, methods and devices
US20150297588A1 (en) Sterile otic formulations
CA3153832C (en) Otic formulations, methods and devices
CN110664743A (zh) 一种用于治疗犬耳炎的伊曲康唑滴耳液及其制备方法
WO2010106460A1 (en) A dermaceutical cream made using sodium fusidate, miconazole nitrate and fluticasone propionate
WO2010106502A1 (en) A novel dermaceutical cream made using sodium fusidate, clotrimazole and clobetasol propionate, a process to make the same and a method of treatment using it
WO2010106503A1 (en) A dermaceutical cream made using sodium fusidate, miconazole nitrate and mometasone furoate
JP2020512997A (ja) 局所用ドキシサイクリン組成物
WO2010106459A1 (en) A dermaceutical cream made using sodium fusidate, clotrimazole and mometasone furoate
WO2012035374A1 (en) A dermaceutical cream made using sodium fusidate, clotrimazole and fluticasone propionate
WO2012035380A1 (en) A novel dermaceutical cream made using sodium fusidate, clotrimazole and mometasone furoate, a process to make the same, and a method of treatment using it

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251217

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260724